Trials / Unknown
UnknownNCT04692051
A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
It is a trial to compare the efficacy and safety of Nab-paclitaxel plus Cisplatin vs Gemcitabine plus Cispatin as first line chemotherapy in advanced biliary tract cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nab-paclitaxel + Cisplatin | Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days. |
| DRUG | Gemcitabine + Cisplatin | Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days. |
Timeline
- Start date
- 2019-09-01
- Primary completion
- 2021-03-01
- Completion
- 2021-09-01
- First posted
- 2020-12-31
- Last updated
- 2020-12-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04692051. Inclusion in this directory is not an endorsement.